
Anna Casu MD
Associate Investigator, AdventHealth Translational Research Institute, Orlando, Florida
Dr. Anna Casu is Assistant Investigator at the Translational Research Institute for Metabolism and Diabetes at Florida Hospital, and she leads the Type 1 Diabetes research at the institution.
She has served as Unit Chief – Diabetes and Islet Transplantation at the University of Pittsburgh Medical Center, Italy – ISMETT-IRCCS Mediterranean Institute for Transplantation and Advanced Specialized Therapies, and Clinical Assistant Professor of Medicine, School of Medicine, Department of Medicine, University of Pittsburgh, PA, USA based in Palermo, Italy.
She received her medical degree, residency and fellowship in Endocrinology and Metabolism at the University of Cagliari in Italy and then worked as a Post-doctoral fellow and Research Associate at the Department of Immunogenetics of the University of Pittsburgh.
Her field of expertise include Type 1 Diabetes, epidemiology, prediction, pathogenic mechanisms, pancreas and islet transplantation. Her recent interest is in Type 1 Diabetes in adults and its relationship with obesity and metabolism.
She has served as Unit Chief – Diabetes and Islet Transplantation at the University of Pittsburgh Medical Center, Italy – ISMETT-IRCCS Mediterranean Institute for Transplantation and Advanced Specialized Therapies, and Clinical Assistant Professor of Medicine, School of Medicine, Department of Medicine, University of Pittsburgh, PA, USA based in Palermo, Italy.
She received her medical degree, residency and fellowship in Endocrinology and Metabolism at the University of Cagliari in Italy and then worked as a Post-doctoral fellow and Research Associate at the Department of Immunogenetics of the University of Pittsburgh.
Her field of expertise include Type 1 Diabetes, epidemiology, prediction, pathogenic mechanisms, pancreas and islet transplantation. Her recent interest is in Type 1 Diabetes in adults and its relationship with obesity and metabolism.
Disclosures
Anna Casu, MD has no conflict of interest to disclose.Recent Contributions to PracticeUpdate:
- Association Between Primary Graft Function and 5-Year Outcomes of Islet Allogeneic Transplantation in Type 1 Diabetes
- Long-Term Outcomes of Islet Transplantation Alone vs Islet Grafting After Kidney Transplantation for Type 1 Diabetes
- Long-Term Risk of CVD in Individuals With Latent Autoimmune Diabetes of Adults
- Empagliflozin as an Adjunct to Insulin Therapy in Type 1 Diabetes
- Islet Transplantation vs Insulin Therapy in Patients With Type 1 Diabetes With Severe Hypoglycemia or Poorly Controlled Glycemia After Kidney Transplantation